TITLE

Clinic Roundup

PUB. DATE
November 2011
SOURCE
BioWorld Today;11/4/2011, Vol. 22 Issue 215, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on clinical studies done by biotechnology companies as of November 4, 2011. Avanir Pharmaceuticals of Aliso Viejo, California started the Phase II trial on the use of AVP-923 for treatment of central neuropathic pain. Results of the first clinical study of Bellicum Pharmaceuticals for its CaspaCIDE technology has been published in "The New England Journal of Medicine." Pluristem Therapeutics Inc. of Haifa, Israel releases its report on PLX-PAD cells.
ACCESSION #
67217444

 

Related Articles

  • Stock Movers.  // BioWorld Today;9/16/2013, Vol. 24 Issue 177, p2 

    A table showing stock movers in the biotechnology industry for September 13, 2013 is presented including Nasdaq Biotechnology, Avanir Pharmaceuticals Inc., and Cell Therapeutics Inc.

  • AVANIR INITIATES PHASE III CLINICAL TRIAL OF NEURODEX.  // Biotech Business;Aug2005, Vol. 18 Issue 8, p5 

    Reports on a clinical trial initiated by pharmaceutical firm Avanir Pharmaceuticals for the drug Neurodex in patients with diabetic neuropathic pain in 2005. Process used by the U.S. Food and Drug Administration to review the clinical trial protocol; Results of the previous trial; Background on...

  • Avanir 'Zenvia' Wall Street with Positive Phase III Results in PBA. Osborne, Randy // BioWorld Today;8/12/2009, Vol. 20 Issue 154, p1 

    The article reports on the positive results from the Phase III data in pseudobulbar affect (PBA) with the drug, Zenvia from Aliso Viejo, California-based Avanir Pharmaceuticals Inc. The stocks of the company increased on August 12, 2009 amid the news of positive results from the clinical trial....

  • Bellicum closes $34.4M Series B, eyes CAR T cells for 'safety switch'. Powers, Marie // BioWorld Today;1/8/2014, Vol. 25 Issue 5, p1 

    The article reports on another 14.7 million U.S. dollars added by privately held Bellicum Pharmaceuticals Inc. from investors to its Series B financing as of January 2014. The capital infusion came from AVG Ventures and Remeditex Ventures which ratchets the total raise from the round to 34.4...

  • Financings Roundup.  // BioWorld Today;6/22/2012, Vol. 23 Issue 121, p3 

    The article offers news briefs on the finances of biotechnology companies including the debt facility secured by Avanir Pharmaceuticals, and the fundraising round secured by Glythera Ltd.

  • FDA OKs 'Expanded' Labeling for Lymphoma Drug. Webb, Marion // San Diego Business Journal;5/21/2001, Vol. 22 Issue 21, p12 

    Reports on news and developments concerning the biotechnology industry in San Diego County, California, for the week previous to May 21, 2001. Food and Drug Administration's approval of a product labeling for the Idec Pharmaceuticals Corp.'s non-Hodgkin's lymphoma drug Rituxan; Controversy over...

  • Analysts, Avanir officials differ on drug's potential. Webb // San Diego Business Journal;11/08/99, Vol. 20 Issue 45, p15 

    Reports on biotechnology industries in San Diego, California, as of November 8, 1999. Includes the United States Food and Drug Administration's data audit of area-based Avanir Pharmaceuticals Inc.'s oral herpes drug; Plan of plant scientists from the San Diego-based University of California,...

  • Gerald Yakatan Looks at Life After Avanir. Webb, Marion // San Diego Business Journal;5/23/2005, Vol. 26 Issue 21, p11 

    Reports on Gerald Yukatan's plan to venture into the biotechnology after his resignation as president and chief executive of San Diego, California-based Avanir Pharmaceuticals Inc. Plan to join a venture capital group; Decision to stay with Avanir as a drug development consultant.

  • WEEK IN REVIEW.  // BioWorld Insight;3/12/2012, Vol. 20 Issue 11, p5 

    The article offers information on the financings and the deals covered by various biotechnology industries as of March 2012 in the U.S. BELLICUM Pharmaceuticals Inc. raised 20 million dollars in a Series B financing. Mersana Therapeutics Inc. signed a 270 million dollars antibody-drug conjugate...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics